FQETT	PTO)-144	9							nt of Comme		Atty. Dock		Serial 1 09/754	
	<i>C</i>											Applicant	s: Marc Feldmai	nn et al	••
3 20	03 A		IN							OSURE CI's if necessar		Filing Date January		Group	
	کیہ									U.S. PA	FENT DOCUMENTS				
DEAN Initial	ner		Doc	umer	nt N	umbe	er			Date	Name	Class	Subclass	Filing D	
₽	· *		5	0	9	6	9	0	6	3/17/92	Mandell, et al.;			 	
<u> </u>			4	6	9	5	4	5	9	9/22/87	Steinman, et al.;			 	_
十		ļ	5	6	5	6	2	7	2	8/6/97	Le, et al.;	-		<u> </u>	
\neg	-		5	5	0	2	0	6	6	3/26/96	Heinemann, et al.	-		↓	
			5	6	5	8	5	7	0	8/19/97	Newman, et al. (Exhibit 1);			<u> </u>	
1			5	5	8	0	8	7	3	12/3/96	Bianco, et al.;	-			
\Box			5		9	8	3	9	6	3/29/94	Kotzin, et al.		L RE	CET	VEL
			<u></u>			<u> </u>	<u> </u>	ļ	<u> </u>		(Exhibit 2);				
			5	4	6	8	4	8	1	11/21/95	Sharma, et al. (Exhibit 3);		JUN	25	2003
\dashv		-	5	2	6	0	4	2	2	11/9/93	Clark, et al.		301	1 0	<u> </u>
			ľ	_	۲	۲	Γ	_	٢	11////	(Exhibit 4);		TECHLOE	HITCO	1000/
			5	2	0	4	3	2	9	4/20/93	Ackerman, et al. (Exhibit 5)		TECH CE	MIEH	1000/4 ~
			5	9	9	4	5	1	0	11/30/99	Adair, et al.				
					L_	ــــــــــــــــــــــــــــــــــــــ	ļ		_		(Exhibit 6);			<u> </u>	
						╄-	-		₩					 	
	 -	<u>L</u>	L		<u> </u>	<u> </u>	<u></u>		1	FOREIGN :	PATENT DOCUMEN	TS	1	<u> </u>	
			Do	cum	ent	Nu	mbe	er		Date	Country	Class	Subclass	Transl	ation
	ĺ													Yes	No
		wo	9	2	0	7	0	7	6	4/30/92	PCT				
	\vdash	wo	9	1	1	0	7	2	2	7/25/91	PCT				
	-			0	1	5	1	5	2	12/13/90	PCT			 	
	<u> </u>	-			_		Ľ	۰.		<u> </u>				-	
		-	0		4	0	3_	4	4	10/7/87	EPO		 	 	
-		AS CN			9 2	7	6 3	9	9	9/22/87 1/19/91	AS CN			===	
\dashv	-	DE			0	6			9	2/28/90	DE			 	
-					4				9	6/15/90	GB				—
\dashv						1								1	
寸									T						
															<u>L</u>
				O'	ТН	ER	DO	CUI	ME	NTS (Includ	ing Author, Title, Dat	e, Pertinent I	Pages, Etc.)		
7	T		Are	nd,	w.	P., e	t al.	(19	90)	Arthritis Rhe	um. 33(3):305-315 (Ex	hibit 7);			
		~								213-216 (Ex			<u> </u>		
- 1											tol. 34:747-755 (Exhib				
-	\perp										nol. 97:1-3 (Exhibit 10				
#											25:876-878, XP002048				
#			CO	oper	, К. М	. <u>u. (</u>	199	<u>3) (</u>	.1111. 143 1	nt Arch All	<u>/ 11:543-559 (Exhibit 1 ergy Immunol.</u> 104:112	125 (Evhibi	t 12):		
			E111:	A++	OV.	ı., et	al.	(TA)	74)]	III. AICH AH	cigy minimunor. 104:112	-125 (EAIIIUI Eubibit 12).	· 14),		
		<u>. </u>	Elli Fel	ott,	nn	М	et a	1.71	996) Ann Rev	mmunol. 14:397 <i>-44</i> 0 (CXIIIDIL 1.37.			
			Fel	dma	nn,	М.,					<u>mmunol.</u> 14:397-440 (EXHIBIT 13),			
		· · ·	Fel Fle	dma sch	nn, (19	M., 92) <u>[</u>	Bloc	<u>od</u> 7	9:33	66-3368	7(22):12-15 (Exhibit 1				

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 600. Described through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Marc Feldmann

Applicants: Marc Feldmann, et al. Serial No.: 09/754,004

Filed: January 3, 2001

Exhibit A

E	Patent and Trademark Office	65019-DA-PCT-US	09/754,004									
~~~ (S)	INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicants: Marc Feld										
3 2003	(Ose several success if incressary)	Filing Date January 3, 2001	Group 644									
MARK OF	OTHER DOCUMENTS (Including Author, Title,											
MARI	Harris, et al. (1993) <u>Tibtech</u> 11:42-44;											
1	Herzog, C., et al. (1987) <u>Lancet</u> 2(8573):1461-1462 (Exh	nibit 15);										
+	Hozzof, et al. (1987) Lancet 11:1461-1642											
$\bot$												
	Kahan, B.D. (1992) <u>Curr. Opin. Immunol.</u> 4:553-560 (Exhibit 16);											
	Kalden, J.R., et al. (1995) <u>Curr. Opin. Rheum.</u> 7: (3)191-											
	Littman, B.H., et al. (1995) <u>Arthritis Rheum.</u> 38:29-37 (E	xhibit 17);										
11	Maini, R.N. (1996) J. Royal College of Physicians of London 30(4):344-351;											
+	Maini, R.N. (1995) <u>Arth. Rheum.</u> Suppl. 38(9):S186 (Abs	stract 200);										
	Matsumiya, G., et al. (1996) <u>Transplant Proceed.</u> 28(2):751-753 (Exhibit 18);											
1-1-	Moreland, L.W., et al. (1995) Arthritis Rheum. 38:1581-1	1588 (Exhibit 19);										
	Moreland, L.W., et al. (1996) J. Rheumatol. (Supplement		BECE									
		al 44) 23.76-65 (Exhibit 20),	RECE									
	Piguet, et al. (1992) <u>Immunology</u> 77:510-514		JUN 2 5									
++	Qin, S., et al. (1987) <u>Eur. J. Immunol.</u> 17:1159-1165 (Ext	hibit 21);										
			TECH CENTER									
	Richardson, C., et al. (1995) Br. J. Clin. Prac. 49:135-139	(Exhibit 22);										
<del>      -  </del>	Sander, O., et al. (1995) Arthritis Rheum. 38:S266 (Abstr	eact 678) (Eyhibit 23):										
	Saluer, O., et al. (1993) <u>Attititis Rieum.</u> 38.3200 (Absu	act 0/0) (Exhibit 25),										
11	Sosman, J.A., et al. (1993) J. Pediatric Hematol. Oncol. 1	5(2):185-195 (Exhibit 24);										
<del>      -     -                          </del>	Section C.M. at al. (1994) Archetic Phases 27,8252 (Fushis	ibit 25):										
	Stein, C.M., et al. (1994) Arthritis Rheum. 37:S252 (Exhi	rbit 25),										
1	Strober, et al. (1990) <u>Immunol. Reviews</u> 118:233-255;											
	Stuart, et al. (1986) <u>Laboratory Investigation</u> 34:1-13 (Exhibit 26);											
	Thorbecke, et al. (1992) Proc. Natl. Acad. Sci. USA 85:7375-7379;											
	Waldmann, T.A. (1991) <u>Science</u> 252:1657-1662;											
+-	Weinblatt, M.E., et al. (1994) Arthritis Rheum. 37:1492-1	1498 (Exhibit 27); and										
1												
1/2	Decision on Appeal, issued March 21, 2003, for U.S. Seri	ial No. 09/093,458, filed June 8,	1998 (Exhibit 28).									
<u> </u>												
KAMINER P	DATE CONSIDERED 1/2/03											